Another two patients (0.6%) received patisiran, a transthyretin (TTR)-directed double-stranded, small interfering RNA, for the treatment of the polyneuropathy of hereditary TTR-mediated amyloidosis (hATTR). This evidence concerns the gene TTR and amyloidosis.